Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study

Human Gene Therapy

Volumn 10, Issue 6, 1999, Pages 983-993

  Schreiber, Susanne ^a   Kämpgen, Eckhart ^b   Wagner, Ernst ^c   Pirkhammer, Detlev ^a   Trcka, Jiri ^b   Korschan, Heidemarie ^a   Lindemann, Albrecht ^d   Dorffner, Roland ^e   Kittler, Harald ^a   Kasteliz, Frank ^c   Küpcü, Zaruhi ^c   Sinski, Aleksandra ^c   Zatloukal, Kurt ^f   Buschle, Michael ^g   Schmidt, Walter ^g   Birnstiel, Max ^g   Kempe, Rudolf E ^h   Voigt, Thor ^h   Weber, Harald A ^h   Pehamberger, Hubert ^a   Mertelsmann, Roland ^d   Bröcker, Eva B ^b   Wolff, Klaus ^a   Stingl, Georg ^a   more..

^a Universitatsklinik fur Dermatologie   (Austria)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^d UNIVERSITY OF FREIBURG   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF GRAZ   (Austria)

^g RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CANCER VACCINE; INTERLEUKIN 2; VIRUS ANTIBODY;

ADENOVIRUS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL SUSPENSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DNA TRANSFECTION; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; GENE THERAPY; HUMAN; HUMAN TISSUE; MALE; MELANOMA; MELANOMA CELL; METASTASIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRURITUS; TUMOR REGRESSION; VIRUS INFECTION; VITILIGO; X RAY;

ADULT; AGED; ANTIBODIES, NEOPLASM; CANCER VACCINES; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; INJECTIONS, INTRALESIONAL; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 2442744586     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018382     Document Type: Article

References (37)

1. ABDEL-WAHAB, Z., WELTZ, C., HESTER, D., PICKETT, N., VERVAERT, C., BARBER, J.R., JOLLY, D., and SEIGLER, H.F. (1997). A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells. Cancer 80, 401-412.
2. ARIENTI, F., SULÉ-SUSO, J., BELLI, F., MASCHERONI, L., RIVOLTINI, L., MELANI, C., MAIO, M., CASCINELLI, N., COLOMBO, M.P., and PARMIANI, G. (1996). Limited antitumor T cell response in melanoma patients vacinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther. 7, 1955-1963.
3. BALCH, C.M., CASCINELLI, N., DRZEWIECKI, K.T. ELDH, J., MACKIE, R.M., MCCARTHY, W.H., MCLEOD, G.R., MORTON, D.L., SEIGLER, H.F., SHAW, H.M., SIM, F.H., SOBER, A.J., SOONG, S.J., TAKEMATSU, H., TONAK, J., and WONG, J. (1992). A comparison of prognostic factors worldwide. In Cutaneous Melanoma. C.M. Balch, A.N. Houghton, G.W. Milton, A.J. Sober, and S.J. Soong, eds. (J.B. Lippincott, Philadelphia) pp. 188-199.
4. BECKER, J.C., DUMMER, R., HARTMANN, A.A., BURG, G., and SCHMIDT, R.E. (1991). Shedding of ICAM-1 from human melanoma cell lines induced by IFN-γ and TNF-α: Functional consequences on cell mediated cytotoxicity. J. Immunol. 147, 4398-4401.
5. BELLI, F., ARIENTI, F., SULÉ-SUSO, J., CLEMENTE, C., MASCHERONI, L., CATTELAN, A., SANANTONIO, C., GALLINO, G.F., MELANI, C., RAO, S., COLOMBO, M.P., MAIO, M., CASCINELLI, N. and PARMIANI, G. (1997). Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol. Immunother. 44, 197-203.
6. BERD, D., MAGUIRE, H.C., JR., and MASTRANGELO, M.J. (1986). Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46, 2572-2577.
7. BERD, D., MAGUIRE, H.C., MCCUE, P., and MASTRANGELO, M.J. (1990). Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J. Clin. Oncol. 8, 1858-1867.
8. BERD, D., MAGUIRE, H.C., SCHUCHTER, L.M., HAMILTON, R., HAUCK, W.W., SATO, T., and MASTRANGELO, M.J. (1997). Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J. Clin. Oncol. 15, 2359-2370.
9. BYSTRYN, J.C., ORATZ, R., ROSES, D., HARRIS, M., HENN, M., and LEW, R. (1992). Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69, 1157-1164.
10. ELIAS, E.G., SUTER, C.M., and FABIAN, D.S. (1997). Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. J. Surg. Oncol. 64, 17-22.
11. ELLEM, K.A.O., O'ROURKE, M.G.E., JOHNSON, G.R., PARRY, G., MISKO, I.S., SCHMIDT, C.W., PARSONS, P.G., BURROWS, S.R., CROSS, S., FELL, A., LI, C.L., BELL, J.R., DUBOIS, P.J., MOSS, D.J., GOOD, M.F., KELSO, A., COHEN, L.K., DRANOFF, G., and MULLIGAN, R.C. (1997). A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage colony-stimulating factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immunother. 44, 10-20.
12. FEARON, E.R., PARDOLL, D., ITAYA, T., GOLUMBEK, P., LEVITSKY, H.L., SIMONS, J.W., KARASUYAMA, H., VOGELSTEIN, B., and FROST, P. (1990). Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an antitumor response. Cell 60, 397-403.
13. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R., and GILBOA, E. (1990). Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
14. HARNING, R., MAINOLFI, E., BYSTRYN, J.C., HENN, M., MERLUZZI, V.J., and ROTHLEIN, R. (1991). Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. Cancer Res. 51, 5003-5005.
15. HELLING, F., ZHANG, S., SHANG, A., ADLURI, S., CALVES, M., KOGANTY, R., LONGENECKER, B.M., YAO, T.J., OETTGEN, H.F., and LIVINGSTON, P.O. (1995). GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55, 2783-2788.
16. JAEGER, E., BERNHARD, H., ROMERO, P., RINGHOFFER, M., ARAND, M., KARBACH, J., ILSEMANN, C., HAGEDORN, M., and KNUTH, A. (1996). Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66, 162-169.
17. JOHNSON, J.P., STADE, B.G., HOLZMANN, B., SCHWÄBLE, W., and RIETHMÜLLER, G. (1989). De novo expression of cell adhesion molecule ICAM-1 in melanoma and increased risk of metastasis. Proc. Natl. Acad. Sci. U.S.A. 86, 641-644.
18. LIVINGSTON, P.O., WONG, G., ADLURI, S., TAO, Y., PADAVAN, M., PARENTE, R., HANLON, C., CALVES, M., HELLING, F., RITTER, G., OETTGEN, H.F., and OLD, L.J. (1994). Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12, 1036-1044.
19. MAASS, G., SCHMIDT, W., BERGER, M., SCHILCHER, F., KOSZIK, F., SCHNEEBERGER, A., STINGL, G., BIRNSTIEL, M.L., and SCHWEIGHOFFER, T. (1995). Priming of tumor-specific T cells in the draining lymph nodes after immunization with IL-2-secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. U.S.A. 92, 5540-5544.
20. MARCHAND, M., WEYNANTS, P., RANKIN, E., ARIENTI, F., BELLI, F., PARMIANI, G., CASCINELLI, N., BOURLOND, A., VANWIJCK, R., HUMBLET, Y., CANON, J.L., LAURENT, C., NAEYAERT, J.M., PLAGNE, R., DERAEMAEKER, R., KNUTH, A., JÄGER, E., BRASSEUR, F., HERMAN, J., COULIE, P.G., and BOON, T. (1995). Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 63, 883-885.
21. MCCUNE, C.S., O'DONNELL, R.W., MARQUIS, D.M., and SAHASRABUDHE, D.M. (1990). Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32, 62-66.
22. MILLER, K., ABELES, G., ORATZ, R., ZELENIUCH-JACQUOTTE, A., CUI, J., ROSES, D.F., HARRIS, M.N., and BYSTRYN, J.C. (1995). Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75, 495-502.
23. MORTON, P.L., FOSHAG, L.J., HOON, D.S.B., NIZZE, J.A., WANEK, L., CHANG, C., DAVTYAN, D., GUPTA, R., ELASHOFF, R., and IRIE, R. (1992). Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 216, 463-482.
24. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G., and SCHADENDORF D. (1998). Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332.
25. PATEL, B.T., LUTZ, M.B., SCHLAG, P., and SCHIRRMACHER, V. (1992). An analysis of autologous T-cell anti-tumor responses in colon-carcinoma patients following active specific immunization (ASI). Int. J. Cancer 51, 878-885.
26. PATEL, P.M., FLEMMING, C.L., FISHER, C., PORTER, C.D., THOMAS, J.M., GORE, M.E., and COLLINS, M.K. (1994). Generation of interleukin-2-secreting melanoma cell populations from resected metastatic tumors. Hum. Gene Ther. 5, 577-584.
27. ROSENBERG, S.A., LOTZE, M., MUUL, L., CHANG, A.A., AVIS, F.P., LEITMANN, S., LINEHAN, W.M., ROBERTSON, C.N., LEE, R.E., RUBIN, J.T., SEIPP, C.A., SIMPSON, C.G., and WHITE, D.E. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 316, 889-897.
28. ROSENBERG, S.A., PACKARD, B.S., AEBERSOLD, P.M., SOLOMON, D., TOPALIAN, S.L., TOY, S.T., SIMON, P., LOTZE, M.T., YANG, J.C., SEIPP, C., SIMPSON, C., CARTER, C., BOCK, S., SCHWARTZENTRUBER, D., WIE, J.P., and WHITE, D.E. (1988). Use of the tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676-1680.
29. ROSENBERG, S.A., LOTZE, M., YANG, J.C., AEBERSOLD, P.M., LINEHAM, W.M., SEIPP, C.A., and WHITE, D.E. (1989). Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485.
30. ROSENBERG, S.A., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., RESTIFO, N.P., DUDLEY, M.E., SCHWARZ, S.L., SPIESS, P.J., WUNDERLICH, J.R., PARKHURST, M.R., KAWAKAMI, Y., SEIPP, C.A., EINHORN, J.H., and WHITE, D.E. (1998). Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321-327.
31. SATO, T., MAGUIRE, H.C., MASTRANGELO, M.J., and BERD, D. (1995). Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin. Immunol. Immunopathol. 74, 35-43.
32. SCHMIDT, W., SCHWEIGHOFFER, T., HERBST, E., MAASS, G., BERGER, M., SCHILCHER, F., SCHAFFNER, G., and BIRNSTIEL, M.L. (1995). Cancer vaccines: The interleukin 2 dosage effect. Proc. Natl. Acad. Sci. U.S.A. 92, 4711-4714.
33. SIMONS, J.W., JAFFEE, E.M., WEBER, C.E., LEVITSKY, H.I., NELSON, W.G., CARDUCCI, M.A., LAZENBY, A.J., COHEN, L.K., FINN, C.C., CLIFT, S.M., HAUDA, K.M., BECK, L.A., LEIFERMAN, K.M., OWENS, A.H., JR., PIANTADOSI, S., DRANOFF, G., MULLIGAN, R.C., PARDOLL, D.M., and MARSHALL, F.F. (1997). Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546.
34. STINGL, G., BROECKER, E.B., MERTELSMANN, R., WOLFF, K., SCHREIBER, S., KAEMPGEN, E., SCHNEEBERGER, A., DUMMER, W., BRENNSCHEID, U., VEELKEN, H., BIRNSTIEL, M.L., ZATLOUKAL, K., SCHMIDT, W., MAASS, G., WAGNER, E., BUSCHLE, M., GIESE, M., KEMPE, E.R., WEBER, H.A., and VOIGT, T. (1996). Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene (trial protocol). Hum. Gene Ther. 7, 551-563.
35. VEELKEN, H., MACKENSEN, A., LAHN, M., KÖHLER, G., BECKER, D., FRANKE, B., BRENNSCHEIDT, U., KULMBURG, P., ROSENTHAL, F.M., KELLER, H., HASSE, J., SCHULTZE-SEEMANN, W., FARTHMANN, E.H., MERTELSMANN, R., and LINDEMANN, A. (1997). A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int. J. Cancer 70, 269-277.
36. WAGNER, E., ZATLOUKAL, K., COTTON, M., KIRLAPPOS, H., MECHTLER, K., CURIEL, D.T., and BIRNSTIEL, M.L. (1992). Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc. Natl. Acad. Sci. U.S.A. 92, 6099-6103.
37. ZATLOUKAL, K., SCHNEEBERGER, A., BERGER, M., SCHMIDT, W., KOSZIK, F., KUTIL, R., COTTEN, M., WAGNER, E., BUSCHLE, M., MAASS, G., PAYER, E., STINGL, G., and BIRNSTIEL, M.L. (1995). Elicitation of a systemic and protective anti-melanoma immune response by an interleukin-2 based vaccine: Assessment of critical cellular and molecular parameters. J. Immunol. 154, 3406-3419.